OliX Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
OliX Pharmaceuticals's earnings have been declining at an average annual rate of -19.5%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 53.7% per year.
Key information
-19.5%
Earnings growth rate
-17.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 53.7% |
| Return on equity | -37.9% |
| Net Margin | -111.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How OliX Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 17,064 | -19,102 | 14,178 | 18,478 |
| 30 Sep 23 | 7,251 | -27,356 | 14,719 | 16,504 |
| 30 Jun 23 | 9,663 | -27,712 | 14,026 | 18,120 |
| 31 Mar 23 | 9,249 | -26,291 | 12,727 | 18,174 |
| 31 Dec 22 | 9,320 | -25,720 | 12,346 | 17,379 |
| 30 Sep 22 | 9,507 | -26,770 | 12,151 | 17,251 |
| 30 Jun 22 | 5,873 | -30,664 | 12,356 | 17,857 |
| 31 Mar 22 | 5,007 | -28,286 | 12,021 | 16,833 |
| 31 Dec 21 | 3,674 | -28,613 | 11,488 | 14,992 |
| 30 Sep 21 | 4,043 | -30,163 | 11,134 | 15,017 |
| 30 Jun 21 | 4,148 | -25,181 | 10,412 | 12,125 |
| 31 Mar 21 | 3,288 | -24,741 | 9,577 | 10,957 |
| 31 Dec 20 | 2,474 | -19,385 | 8,227 | 9,478 |
| 30 Sep 20 | 1,519 | -16,871 | 7,247 | 10,263 |
| 30 Jun 20 | 958 | -16,147 | 6,986 | 9,824 |
| 31 Mar 20 | 1,196 | -14,885 | 6,562 | 9,523 |
| 31 Dec 19 | 1,130 | -14,353 | 6,665 | 8,973 |
| 30 Sep 19 | 1,039 | -10,973 | 5,540 | 6,932 |
| 30 Jun 19 | 758 | -9,399 | 4,588 | 6,096 |
| 31 Mar 19 | 418 | -8,170 | 3,960 | 4,977 |
| 31 Dec 18 | 302 | -7,742 | 3,200 | 5,082 |
| 31 Dec 17 | 244 | -5,164 | 2,048 | 3,334 |
Quality Earnings: A226950 is currently unprofitable.
Growing Profit Margin: A226950 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A226950 is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.
Accelerating Growth: Unable to compare A226950's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A226950 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A226950 has a negative Return on Equity (-37.95%), as it is currently unprofitable.